Uruguay's metaBIX bets $1.3M on Brazil as AI reshapes Latin America's healthtech boom
When a Montevideo lab coats itself in venture capital, the rest of South America tends to notice. metaBIX Biotech, a Uruguayan startup using artificial intelligence to predict disease before it strikes, just pulled in US$1.3 million in fresh funding — a modest sum by global standards, but a loud signal for a region where healthtech is suddenly the asset class everyone wants to talk about.
The money is earmarked for Brazil, the continent's healthcare heavyweight and a market where the government recently pledged to use technology to speed up rare-disease diagnosis. Brazil's health ministry estimates at least 13 million people live with rare conditions, many of them waiting years for answers. metaBIX's pitch is simple: feed clinical data through AI models, spot risks early, and give doctors tools to act before a condition becomes a crisis. Co-founder and CEO Laura Macció put it bluntly: Brazil will be the company's main market by 2026, with strategic partnerships in larger economies to follow.
To understand why this matters, you have to step back. Latin America's healthtech sector drew US$253.3 million in venture investment in 2024, a 36.6% jump from the year before. Globally, AI-related healthcare deals blew past US$300 million in 2025 — a record. The region is no longer just importing innovation from Silicon Valley; it is exporting its own, and Uruguay — small, stable, and quietly producing a pipeline of biotech founders — is punching well above its weight. metaBIX is the kind of company that makes international investors rethink the map.
The broader picture is about more than one startup. Across the region, a new wave of founders is attacking healthcare's oldest inefficiencies. In Medellín, Colombian entrepreneurs built 360 Health Data, whose Coralia Health platform uses automation to translate medical knowledge into Spanish, breaking down the language barriers that leave many patients and doctors in the dark. In the women's health space, Ourself Health — founded by Adriana Torosian — just launched Stella, an AI app that helps women decode how hormones affect their daily lives. These are not vanity projects; they are responses to structural gaps that public systems have failed to close.
What makes this moment distinct is the convergence of three forces: cheaper AI tools, a post-pandemic appetite for remote and predictive care, and governments that are finally willing to pay for efficiency. Brazil and Mexico lead the pack, but Colombia, Chile, and Argentina are emerging as secondary hubs, each with its own cluster of startups and a growing pool of female entrepreneurs — a notable shift in a sector long dominated by male-led firms. The panel discussions in Medellín late last year projected 14% growth for healthtech through 2032, with telemedicine, clinical AI, digital mental health, and remote monitoring as the fastest-moving segments.
For the international reader watching South American capital flows, the takeaway is this: the region's wealth story is no longer just commodities and family conglomerates. A generation of founders is building companies that merge science with data, and venture money is following. metaBIX's expansion into Brazil is a small deal, but it carries an outsized message — that the next big health breakthrough may well be coded in Spanish or Portuguese before it ever reaches English.
The road ahead is not without hurdles. Regulatory frameworks lag, infrastructure outside major cities is patchy, and funding rounds remain tiny compared to North American or European peers. But the direction is clear. As Macció and her peers push into new markets, they are betting that the region's size, dynamism, and desperation for better healthcare will turn these early experiments into durable businesses. For anyone tracking wealth in South America, healthtech is no longer a side note — it is a headline.
